Chemotherapy and immunotherapy in metastatic colorectal cancer. Pohlmann PR, Mernaugh RL, Goff LW (2009) N Engl J Med 360: 2134; author reply 2135-6 Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T (2018) Nat Med 24: 749-757 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) J Clin Oncol 23: 3502-8 BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ (2012) J Clin Oncol 30: 34-41 Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) J Clin Oncol 23: 7889-96 Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) J Clin Oncol 26: 3743-8 Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Nazer B, Humphreys BD, Moslehi J (2011) Circulation 124: 1687-91 A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA (2013) Clin Cancer Res 19: 258-67 A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma. Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB (2016) Pigment Cell Melanoma Res 29: 101-3 Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Brantley MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A (2007) Ophthalmology 114: 2168-73 Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, Feng S (2012) Cancer 118: 1083-90 Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Wicherts DA, de Haas RJ, Sebagh M, Saenz Corrales E, Gorden DL, Lévi F, Paule B, Azoulay D, Castaing D, Adam R (2011) Br J Surg 98: 399-407 Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE (2010) Cancer Epidemiol Biomarkers Prev 19: 358-65 Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP (2009) J Thorac Oncol 4: 689-96 Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Investigators of the BRiTE study (2009) Oncologist 14: 862-70 Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F (2012) Oncologist 17: 1534-40 Renal cell carcinoma. Rini BI, Rathmell WK, Godley P (2008) Curr Opin Oncol 20: 300-6 A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS (2013) J Immunother 36: 490-5 Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF (2009) J Immunother 32: 181-5 Targeting vascular endothelial growth factor in colorectal cancer. Berlin JD (2002) Oncology (Williston Park) 16: 13-5 Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. Rini BI, Sosman JA, Motzer RJ (2005) BJU Int 96: 286-90 Safety of intravitreal injection of bevacizumab in rabbit eyes. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA (2006) Retina 26: 882-8 Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) J Surg Oncol 91: 173-80 Antiangiogenic therapies in early-stage breast cancer. Derleth C, Mayer IA (2010) Clin Breast Cancer 10 Suppl 1: E23-31 Anti-angiogenic treatment of gastrointestinal malignancies. Salmon JS, Lockhart AC, Berlin J (2005) Cancer Invest 23: 712-26 Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A (2010) Oncology 78: 329-39 Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Hainsworth JD, Spigel DR, Sosman JA, Burris HA, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, Greco FA (2007) Clin Genitourin Cancer 5: 427-32
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.